Introgen Therapeutics Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Introgen Therapeutics

INGN 6.690

+0.1%

12:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jibacoa who wrote (791)	7/17/2008 11:23:01 AM
From: Jibacoa	of 802

INGN Is trying to move some today in anticipation of next week's presentation.<g> Introgen to Present ADVEXIN Phase 3 Study Results at American Association for Cancer Research's Cancer Clinical Trials and Personalized Medicine Conference. Thursday July 17, 7:30 am ET Supplemental Statistical Analysis Supports Superior Efficacy of ADVEXIN in p53 Biomarker Patient Population AUSTIN, Texas--(BUSINESS WIRE)--Introgen Therapeutics, Inc. (NASDAQ:INGN - News), a developer of targeted molecular therapies for cancer, today announced that the company will present the results from its recently completed Phase 3 trial of ADVEXIN in recurrent head and neck cancer at the American Association for Cancer Research (AACR) Centennial Conference on Translational Cancer Medicine 2008: Cancer Clinical Trials and Personalized Medicine. The conference will be held July 20-23, 2008 at the Hyatt Regency Monterey in Monterey, CA. Introgen’s presentation will review the previously announced findings from the Company’s Phase 3 trial which demonstrated that ADVEXIN successfully achieved its primary and secondary efficacy endpoints in the study’s pre-specified p53 biomarker population. In addition, Introgen will present supplemental statistical analyses that are included in the Company’s Biologics License Application and Marketing Authorization Application in the U.S. and Europe, respectively. Details of the presentation are as follows: Abstract Title: “Tumor p53 biomarkers predict efficacy of ADVEXIN p53 therapy providing for personalized treatment of patients with recurrent squamous cell carcinoma of the head and neck” Date: Tuesday, July 22, 2008 Time: 5:00-7:00 pm

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next